SAN DIEGO, April 18, 2022 (Globe NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automatic benchtop artificial biology systems, today declared its speaker presentation for the Environment Vaccine Congress Washington 2022, which is getting held in Washington, DC. on April 18-21, 2022. The organization will be showcasing its automatic benchtop workstation – the BioXp™ program and it’s automated methods for accelerating vaccine discovery workflows at booth #202.

The have to have for fast vaccine development in reaction to rising pathogens has grow to be significantly obvious all through the COVID-19 pandemic. On the other hand, traditional vaccine discovery, development, and manufacturing methods can be difficult for brands, regulators, and community well being officials, especially for endemic viruses that require adjustments to counter ongoing antigenic variation. Codex DNA’s automated option at the moment supports swift DNA and mRNA synthesis from electronic sequence in a single automatic operate. The BioXp 3250 system enables customers to synthesize higher-high-quality DNA and biologically active mRNA within 24 hours, cutting down turnaround time from months to times, raising throughput and scale, improving high quality, and offering researchers finish workflow handle. Codex DNA also expects it is proprietary Brief Oligonucleotide Ligation Assembly (SOLA) Enzymatic DNA Synthesis (EDS) tactic will even more enable on-desire synthesis of DNA, mRNA and protein and shorten the timeline for discovery and development of mRNA-centered vaccines, diagnostics, therapeutics, and customized medications.

Codex DNA and RNAimmune have been functioning together to enhance the enhancement and validation of Codex DNA’s long run mRNA synthesis kits. In this hard work, the two corporations will also handle the integration of RNAimmune’s proprietary mRNA delivery alternatives into Codex DNA’s automated workflows to further streamline the vaccine discovery procedure.

“We are thrilled to operate with Codex DNA to speed up breakthroughs applying mRNA platforms. With each other, we can include our proprietary provider molecules into Codex DNA’s mRNA synthesis kits to enhance automated production toward actually transfection-prepared mRNA with enhanced uptake and expression,” claimed Dong Shen, Ph.D, CEO of RNAimmune. RNAimmune will showcase the design and style and advancement of their novel Pan-Ras mRNA vaccine for most cancers treatment at the meeting and also emphasize the use of the BioXp™ technique in accelerating their discovery workflows.

Showcased Purchaser PRESENTATION:        
Concentrating on KRAS mutations in most cancers: new mRNA vaccine on the horizon
Keep track of: Cancer and Immunotherapy
Presenter: Dong Shen, MD, PhD​, President & CEO, RNAimmune​
Day/Time: Wednesday, April 20, 3:40 pm
Spot: M4, Liberty Salon I-K

“Together with RNAimmune, we are empowering our buyers to design and style, build, and develop safe and sound, superior-top quality vaccines quicker than ever right before,” claimed Todd R. Nelson, PhD, CEO of Codex DNA. “I’m psyched for convention attendees to listen to right from Dr. Shen about the spectacular do the job getting done in mRNA vaccines. Our sustainable, scalable, and charge-productive method has the possible to entirely completely transform how the entire world responds to rising viral threats in the future.”

Codex DNA at this time delivers a catalog of artificial genomes, like SARS-CoV-2, for investigate use for monoclonal antibody therapies, little-molecule therapies, diagnostic assays, and new vaccines towards particular variants. For more data, be sure to visit the pursuing connection.

About Codex DNA
Codex DNA is empowering experts with the capability to create novel, artificial biology-enabled answers for a lot of of humanity’s finest problems. As inventors of the sector-typical Gibson Assembly^® strategy and the first professional automatic benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, precise and reproducible crafting of DNA and mRNA for various downstream marketplaces. The award-winning BioXp™ procedure consolidates, automates and optimizes the complete synthesis, cloning and amplification workflow. As a outcome, it provides virtually mistake-cost-free synthesis of DNA and RNA at scale within just times and several hours in its place of weeks or months. Scientists about the earth are employing the engineering in their own laboratories to accelerate the design and style-build-examination paradigm for novel, high-worth merchandise for precision medication, biologics drug discovery, vaccine and therapeutic advancement, genome enhancing, and cell and gene treatment. Codex DNA is a general public company based mostly in San Diego. For far more details, check out codexdna.com.

Codex DNA, the Codex DNA emblem, Gibson Assembly, and BioXp are emblems of Codex DNA Inc.

Ahead-Seeking Statements
This press launch incorporates forward-wanting statements. All statements other than statements of historical information contained herein are forward-looking statements reflecting the existing beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include things like statements pertaining to Codex DNA’s progress built on obtaining corporate targets and the upcoming release of merchandise and providers. Such statements are based mostly on present assumptions that involve risks and uncertainties that could cause precise results and results to differ materially. These challenges and uncertainties, numerous of which are past Codex DNA’s control, involve threats described in Codex DNA’s community filings, specifically the section entitled Risk Aspects and somewhere else in its yearly Report on Sort 10-K, which is predicted to be submitted with the Securities and Exchange Fee on March 23, 2022. These ahead-looking statements converse only as of the date hereof and should really not be unduly relied upon. Codex DNA disclaims any obligation to update these forward-searching statements.

Media Call
Richard D. Lepke
Director, Investor Relations
[email protected]